Title : Measurement of molecular biomarkers that predict the tumor response in estrogen receptor-positive breast cancers after dose-dense (biweekly) paclitaxel/carboplatin neoadjuvant chemotherapy.

Pub. Date : 2017 Nov 24

PMID : 29254147






4 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Measurement of molecular biomarkers that predict the tumor response in estrogen receptor-positive breast cancers after dose-dense (biweekly) paclitaxel/carboplatin neoadjuvant chemotherapy. Paclitaxel estrogen receptor 1 Homo sapiens
2 The aim of this study was to determine the predictive value of the clinical and histopathological characteristics of estrogen receptor (ER)-positive patients treated with dose-dense paclitaxel/carboplatin neoadjuvant chemotherapy (NCT). Paclitaxel estrogen receptor 1 Homo sapiens
3 The aim of this study was to determine the predictive value of the clinical and histopathological characteristics of estrogen receptor (ER)-positive patients treated with dose-dense paclitaxel/carboplatin neoadjuvant chemotherapy (NCT). Paclitaxel estrogen receptor 1 Homo sapiens
4 In conclusion, Bcl-2 negative, HER2-positive and smaller (<=2 cm) tumor sizes are independent predictors of pCR in ER-positive patients treated with dose-dense (biweekly) paclitaxel/carboplatin NCT. Paclitaxel estrogen receptor 1 Homo sapiens